The burden of COVID-19 in French Guiana: Vaccine-averted deaths, hospitalizations and costs.

COVID-19 Cost Diffusion of Innovations Mortality Number needed to vaccinate Vaccination Vaccine reluctance

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 21 12 2021
revised: 01 12 2022
accepted: 09 02 2023
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 24 2 2023
Statut: ppublish

Résumé

French Guiana, the least-vaccinated French territory, also has the lowest COVID-19 vaccination coverage in Latin America. We aimed to estimate how many deaths, hospitalizations and costs the vaccines had and could have avoided. We calculated the Number Needed to Vaccinate to prevent one death per year, 1 standard hospitalization, 1 Intensive Care Unit admission given the mean incidence numbers of the past 6 months, and divided the number of persons vaccinated to estimate how many deaths and hospitalizations had been avoided in French Guiana at that time. The crude number needed to vaccinate to prevent one death per year, the crude number needed to vaccinate to prevent one hospitalization per 6 months were computed Based on our observed incidence and ICU admission rate, the crude number needed to vaccinate to prevent one ICU admission per 6 months.After 6 months with an incidence exceeding 400 per million inhabitants, and 148 observed deaths, we estimate that vaccination avoided 46 deaths (IC95%=43.5-48.7). If the number of vaccinated persons had reached the same proportion as mainland France, 141 deaths per year could have been prevented (IC95%=131.9-147.6).With 2085 hospitalization and 370 ICU admissions during the same period, we estimate that the current albeit low vaccination rate avoided 300 hospital (IC95%=280-313) and 77 (IC95%=72-81) ICU admissions. With the same vaccination rates as mainland France, we estimate that 900 hospitalizations and 231 ICU admissions would have been avoided.Similarly, there would have been 139 ICU admission (instead of 370). In sparsely populated French Guiana these numbers are quite substantial and framing the vaccine benefits and wasted opportunities using such concrete numbers may help convincing undecided persons to get vaccinated.

Identifiants

pubmed: 36819215
doi: 10.1016/j.jvacx.2023.100271
pii: S2590-1362(23)00012-8
pmc: PMC9918439
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100271

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Front Public Health. 2021 Mar 11;9:586299
pubmed: 33777876
N Engl J Med. 2021 Dec 2;385(23):2195-2197
pubmed: 34670038
Vaccines (Basel). 2021 Oct 20;9(11):
pubmed: 34835147
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34593513
Vaccines (Basel). 2021 Jun 21;9(6):
pubmed: 34205613
Glob Health Action. 2017;10(1):1270525
pubmed: 28156196
Vaccine. 2004 Jun 2;22(17-18):2192-8
pubmed: 15149776
Nat Commun. 2021 Mar 12;12(1):1634
pubmed: 33712596
Health Educ Behav. 2007 Dec;34(6):881-96
pubmed: 17602096
Br J Surg. 2021 Sep 27;108(9):1056-1063
pubmed: 33761533
Lancet Infect Dis. 2021 Dec;21(12):1627
pubmed: 34739865
Addict Behav. 2002 Nov-Dec;27(6):989-93
pubmed: 12369480
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Vaccine. 2009 Jul 30;27(35):4771-5
pubmed: 19540950
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33915695
Can J Cardiol. 2021 Jul;37(7):1112-1116
pubmed: 33933606
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
Public Health. 2021 May;194:245-251
pubmed: 33965796
Behav Brain Sci. 2011 Apr;34(2):57-74; discussion 74-111
pubmed: 21447233

Auteurs

Mathieu Nacher (M)

CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 French Guiana.
Département Formation Recherche, Université de Guyane, French Guiana.

Nicolas Vignier (N)

CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 French Guiana.

Cyril Rousseau (C)

Santé Publique France, French Guiana.

Antoine Adenis (A)

CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 French Guiana.
Département Formation Recherche, Université de Guyane, French Guiana.

Maylis Douine (M)

CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 French Guiana.

Célia Basurko (C)

CIC INSERM 1424, Centre Hospitalier de Cayenne, 97300 French Guiana.

Bertrand de Toffol (B)

Département Formation Recherche, Université de Guyane, French Guiana.
Service de Neurologie, Centre Hospitalier de Cayenne, 97300 French Guiana.

Narcisse Elenga (N)

Département Formation Recherche, Université de Guyane, French Guiana.
Service de Pédiatrie, Centre Hospitalier de Cayenne, 97300 French Guiana.

Hatem Kallel (H)

Service de Réanimation, Centre Hospitalier de Cayenne, 97300 French Guiana.

Jean Pujot (J)

Service de, Centre Hos Urgences, Centre Hospitalier de Cayenne, 97300 French Guiana.

Magaly Zappa (M)

Service de Radiologie, Centre Hospitalier de Cayenne, 97300 French Guiana.

Magalie Demar (M)

Laboratoire polyvalent, Centre Hospitalier de Cayenne, 97300 French Guiana.
Unité Mixte de RechercheTropical Biome and Immunopathology, Université de Guyane, French Guiana.

Félix Djossou (F)

Service des Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne, 97300 French Guiana.

Pierre Couppié (P)

Département Formation Recherche, Université de Guyane, French Guiana.
Service de Dermatologie, Centre Hospitalier de Cayenne, 97300 French Guiana.

Loïc Epelboin (L)

Département Formation Recherche, Université de Guyane, French Guiana.
Service de Dermatologie, Centre Hospitalier de Cayenne, 97300 French Guiana.

Classifications MeSH